Literature DB >> 23525268

Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.

Qiu Yan1, Daniel Q Bach, Nandita Gatla, Ping Sun, Ji-Wei Liu, Jian-Yun Lu, Amy S Paller, Xiao-Qi Wang.   

Abstract

GM3, the simplest ganglioside, regulates cell proliferation, migration, and invasion by influencing cell signaling at the membrane level. Although the classic N-acetylated form of GM3 (NeuAcLacCer) is commonly expressed and has been well studied, deacetylated GM3 (NeuNH2LacCer, d-GM3) has been poorly investigated, despite its presence in metastatic tumors but not in noninvasive melanomas or benign nevi. We have recently found that d-GM3 stimulates cell migration and invasion by activating urokinase plasminogen activator receptor (uPAR) signaling to augment matrix metalloproteinase-2 (MMP-2) function. However, the mechanisms by which d-GM3/uPAR increase MMP-2 expression and activation are not clear. By modifying the expression of d-GM3 genetically and biochemically, we found that decreasing d-GM3 expression inhibits, whereas overexpressing d-GM3 stimulates, p38 mitogen-activated protein kinase (MAPK) activity to influence MMP-2 expression and activation. p38 MAPK (p38) activation requires the formation of a membrane complex that contains uPAR, caveolin-1, and integrin α5β1 in membrane lipid rafts. In addition, knocking down or inhibiting focal adhesion kinase (FAK), phosphoinositide 3-kinase (PI3K), or Src kinase significantly reduces d-GM3-induced p38 phosphorylation and activation. Taken together, these results suggest that d-GM3 enhances the metastatic phenotype by activating p38 signaling through uPAR/integrin signaling with FAK, PI3K, and Src kinase as intermediates. Elucidation of the mechanisms by which d-GM3, a newly discovered, potential biomarker of metastatic melanomas, promotes cell metastasis will help us to understand the function of d-GM3 in metastatic melanomas and may lead to novel GM3-based cancer therapies. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23525268     DOI: 10.1158/1541-7786.MCR-12-0270-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

1.  Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line.

Authors:  Şükrü Aydın Düzgün; Azmi Yerlikaya; Sezgin Zeren; Zülfü Bayhan; Emrah Okur; İhsan Boyacı
Journal:  Cytotechnology       Date:  2017-04-09       Impact factor: 2.058

Review 2.  Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Authors:  Daniela Alfano; Paola Franco; Maria Patrizia Stoppelli
Journal:  Front Cell Dev Biol       Date:  2022-04-08

3.  IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9.

Authors:  Qiaojia Huang; Fenghua Lan; Xiaoting Wang; Yinghao Yu; Xuenong Ouyang; Feng Zheng; Junyong Han; Youdong Lin; Yanchuan Xie; Feilai Xie; Wei Liu; Xiaoli Yang; Han Wang; Lihong Dong; Lie Wang; Jianming Tan
Journal:  Mol Cancer       Date:  2014-01-31       Impact factor: 27.401

4.  Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology.

Authors:  Thomas Hart; Shihab Dider; Weiwei Han; Hua Xu; Zhongming Zhao; Lei Xie
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

Review 5.  Biological Roles of Aberrantly Expressed Glycosphingolipids and Related Enzymes in Human Cancer Development and Progression.

Authors:  Dinghao Zhuo; Xiang Li; Feng Guan
Journal:  Front Physiol       Date:  2018-05-03       Impact factor: 4.566

6.  Roles of p38α and p38β mitogen‑activated protein kinase isoforms in human malignant melanoma A375 cells.

Authors:  Su-Ying Wen; Shi-Yann Cheng; Shang-Chuan Ng; Ritu Aneja; Chih-Jung Chen; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Int J Mol Med       Date:  2019-10-24       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.